A Phase 2 interventional study of ombitasvir/paritaprevir/ritonavir and dasabuvir and ombitasvir/paritaprevir/ritonavir in Chronic Hepatitis C Infection, sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-07.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety and efficacy of ABT-450/r/ABT-267 with or without ABT-333 and with or without ribavirin (RBV) in adult liver or renal transplant recipients with hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4) infection.
83 studies on the registry are indexed under Hepatitis, Chronic; 10 are open to participants now.
This study's enrollment of 129 is above the median of 84 across 59 interventional studies indexed under Hepatitis, Chronic.
Browse Hepatitis, Chronic studies →AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Liver transplant recipients with HCV genotype 1 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: ribavirin
Liver transplant recipients with HCV genotype 1a or genotype 1b (dependent on prior treatment experience and response) infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: ribavirin
Liver transplant receipts with HCV genotype 1b infection who were treatment naïve or prior responders to interferon treatment without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 24 weeks.
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Liver transplant recipients with HCV genotype 1a infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (dosed 1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: ribavirin
Liver transplant recipients with HCV genotype 1b infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: ribavirin
Liver transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: ribavirin
Liver transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Renal transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: ribavirin
Renal transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Liver transplant recipients with HCV genotype 4 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
Drug: ombitasvir/paritaprevir/ritonavir · Drug: ribavirin
Liver transplant recipients with HCV genotype 4 infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
Drug: ombitasvir/paritaprevir/ritonavir · Drug: ribavirin
Drug pages: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir
Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
Also known as: Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333
Drug page: Ombitasvir/Paritaprevir/Ritonavir
Tablet; ombitasvir coformulated with paritaprevir and ritonavir
Also known as: TECHNIVIE, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267
tablet
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug. Participants with missing data after backward imputation were imputed as nonresponders.
Time frame: 12 weeks after the last actual dose of study drug
Percentage of Participants With Sustained Virologic Response 24 Weeks Post-treatment (SVR24)
SVR24 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 24 weeks after the last dose of study drug. Participants with missing data after backward imputation were imputed as nonresponders.
Time frame: 24 weeks after the last actual dose of study drug
Percentage of Participants With On-treatment Virologic Failure
On-treatment virologic failure was defined as confirmed increase of \> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment, or confirmed HCV RNA ≥ LLOQ at any point during treatment after HCV RNA \< LLOQ, or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks (≥ 36 days) of treatment.
Time frame: Up to 12 weeks (for 12-week treatment) or 24 weeks (for 24-week treatment)
Percentage of Participants With Post-treatment Relapse
Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \< LLOQ at the end of treatment.
Time frame: From the end of treatment through 12 weeks after the last dose of study drug
| Milestone | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm H | Arm I | Arm J | Arm K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 34 | 27 | 13 | 4 | 2 | 22 | 12 | 9 | 3 | 2 | 1 |
| Completed | 34 | 26 | 13 | 4 | 2 | 22 | 12 | 6 | 3 | 2 | 1 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug. Participants with missing data after backward imputation were imputed as nonresponders.
| percentage of participants | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm H | Arm I | Arm J | Arm K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) | 97.1 (85.1 to 99.5) | 96.3 (81.7 to 99.3) | 100 (77.2 to 100.0) | 100 (51.0 to 100.0) | 100 (34.2 to 100.0) | 95.5 (78.2 to 99.2) | 100 (75.8 to 100.0) | 66.7 (35.4 to 87.9) | 100 (43.9 to 100.0) | 100 (34.2 to 100.0) | 100 (20.7 to 100.0) |
SVR24 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 24 weeks after the last dose of study drug. Participants with missing data after backward imputation were imputed as nonresponders.
| percentage of participants | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm H | Arm I | Arm J | Arm K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response 24 Weeks Post-treatment (SVR24) | 97.1 (85.1 to 99.5) | 96.3 (81.7 to 99.3) | 100 (77.2 to 100.0) | 100 (51.0 to 100.0) | 100 (34.2 to 100.0) | 95.5 (78.2 to 99.2) | 100 (75.8 to 100.0) | 66.7 (35.4 to 87.9) | 100 (43.9 to 100.0) | 100 (34.2 to 100.0) | 100 (20.7 to 100.0) |
On-treatment virologic failure was defined as confirmed increase of \> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment, or confirmed HCV RNA ≥ LLOQ at any point during treatment after HCV RNA \< LLOQ, or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks (≥ 36 days) of treatment.
| percentage of participants | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm H | Arm I | Arm J | Arm K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With On-treatment Virologic Failure | 0 (0.0 to 10.2) | 3.7 (0.7 to 18.3) | 0 (0.0 to 22.8) | 0 (0.0 to 49.0) | 0 (0.0 to 65.8) | 0 (0.0 to 14.9) | 0 (0.0 to 24.2) | 0 (0.0 to 29.9) | 0 (0.0 to 56.1) | 0 (0.0 to 65.8) | 0 (0.0 to 79.3) |
Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \< LLOQ at the end of treatment.
| percentage of participants | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm H | Arm I | Arm J | Arm K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Post-treatment Relapse | 3.0 (0.5 to 15.3) | 0 (0.0 to 12.9) | 0 (0.0 to 24.2) | 0 (0.0 to 49.0) | 0 (0.0 to 65.8) | 4.8 (0.8 to 22.7) | 0 (0.0 to 24.2) | 0 (0.0 to 39.0) | 0 (0.0 to 56.1) | 0 (0.0 to 65.8) | 0 (0.0 to 79.3) |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 30 days after the last dose of study drug (up to 28 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ARM A | 0/34 (0%) | 2/34 (5.9%) | 33/34 (97.1%) |
| ARM B | 0/27 (0%) | 1/27 (3.7%) | 27/27 (100%) |
| ARM C | 0/13 (0%) | 0/13 (0%) | 12/13 (92.3%) |
| ARM D | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| ARM E | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| ARM F | 0/22 (0%) | 2/22 (9.1%) | 22/22 (100%) |
| ARM G | 0/12 (0%) | 1/12 (8.3%) | 12/12 (100%) |
| ARM H | 1/9 (11.1%) | 4/9 (44.4%) | 8/9 (88.9%) |
| ARM I | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| ARM J | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| ARM K | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | ARM A | ARM B | ARM C | ARM D | ARM E | ARM F | ARM G | ARM H | ARM I | ARM J | ARM K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NAUSEAGastrointestinal disorders | 0/34 | 0/27 | 0/13 | 0/4 | 0/2 | 1/22 | 0/12 | 1/9 | 0/3 | 0/2 | 0/1 |
| VOMITINGGastrointestinal disorders | 0/34 | 0/27 | 0/13 | 0/4 | 0/2 | 1/22 | 0/12 | 1/9 | 0/3 | 0/2 | 0/1 |
| ATYPICAL PNEUMONIAInfections and infestations | 0/34 | 0/27 | 0/13 | 0/4 | 0/2 | 0/22 | 0/12 | 1/9 | 0/3 | 0/2 | 0/1 |
| OVERDOSEInjury, poisoning and procedural complications | 0/34 | 0/27 | 0/13 | 0/4 | 0/2 | 0/22 | 0/12 | 1/9 | 0/3 | 0/2 | 0/1 |
| ISCHAEMIC CEREBRAL INFARCTIONNervous system disorders | 0/34 | 0/27 | 0/13 | 0/4 | 0/2 | 0/22 | 0/12 | 1/9 | 0/3 | 0/2 | 0/1 |
| ACUTE KIDNEY INJURYRenal and urinary disorders | 0/34 | 0/27 | 0/13 | 0/4 | 0/2 | 0/22 | 1/12 | 1/9 | 0/3 | 0/2 | 0/1 |
| ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 0/34 | 0/27 | 0/13 | 0/4 | 0/2 | 0/22 | 0/12 | 1/9 | 0/3 | 0/2 | 0/1 |
| HYPONATRAEMIAMetabolism and nutrition disorders | 0/34 | 0/27 | 0/13 | 0/4 | 0/2 | 0/22 | 1/12 | 0/9 | 0/3 | 0/2 | 0/1 |
| LEUKOCYTOSISBlood and lymphatic system disorders | 0/34 | 0/27 | 0/13 | 0/4 | 0/2 | 1/22 | 0/12 | 0/9 | 0/3 | 0/2 | 0/1 |
| LOWER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/34 | 0/27 | 0/13 | 0/4 | 0/2 | 1/22 | 0/12 | 0/9 | 0/3 | 0/2 | 0/1 |
| Event | ARM A | ARM B | ARM C | ARM D | ARM E | ARM F | ARM G | ARM H | ARM I | ARM J | ARM K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ANAEMIABlood and lymphatic system disorders | 8/34 | 8/27 | 1/13 | 3/4 | 2/2 | 4/22 | 0/12 | 2/9 | 1/3 | 0/2 | 0/1 |
| CONSTIPATIONGastrointestinal disorders | 2/34 | 1/27 | 1/13 | 0/4 | 0/2 | 4/22 | 1/12 | 2/9 | 0/3 | 0/2 | 1/1 |
| ASTHENIAGeneral disorders | 8/34 | 7/27 | 1/13 | 0/4 | 2/2 | 2/22 | 1/12 | 0/9 | 0/3 | 0/2 | 0/1 |
| FATIGUEGeneral disorders | 17/34 | 14/27 | 4/13 | 4/4 | 0/2 | 14/22 | 2/12 | 6/9 | 1/3 | 1/2 | 1/1 |
| INFLUENZA LIKE ILLNESSGeneral disorders | 2/34 | 1/27 | 0/13 | 0/4 | 0/2 | 0/22 | 0/12 | 0/9 | 0/3 | 0/2 | 1/1 |
| JAUNDICEHepatobiliary disorders | 0/34 | 3/27 | 0/13 | 0/4 | 0/2 | 1/22 | 0/12 | 0/9 | 0/3 | 0/2 | 1/1 |
| DRY SKINSkin and subcutaneous tissue disorders | 1/34 | 0/27 | 0/13 | 2/4 | 1/2 | 1/22 | 0/12 | 0/9 | 0/3 | 0/2 | 1/1 |
| PRURITUSSkin and subcutaneous tissue disorders | 2/34 | 4/27 | 1/13 | 4/4 | 2/2 | 5/22 | 4/12 | 1/9 | 0/3 | 1/2 | 0/1 |
| DRY EYEEye disorders | 0/34 | 0/27 | 0/13 | 0/4 | 1/2 | 0/22 | 0/12 | 0/9 | 0/3 | 0/2 | 0/1 |
| EYE PRURITUSEye disorders | 0/34 | 0/27 | 0/13 | 0/4 | 1/2 | 0/22 | 0/12 | 0/9 | 0/3 | 0/2 | 0/1 |
| Age, Continuous(years) | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm H | Arm I | Arm J | Arm K | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 59.6 ± 6.62 | 58.0 ± 6.66 | 61.8 ± 5.76 | 59.8 ± 10.78 | 78.0 ± 1.41 | 58.3 ± 9.35 | 62.2 ± 7.64 | 58.0 ± 8.00 | 57.3 ± 9.29 | 63.5 ± 7.78 | 50.0 ± NA | 59.6 ± 7.73 |
| Sex: Female, Male(Participants) | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm H | Arm I | Arm J | Arm K | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 7 | 4 | 5 | 0 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 25 |
| Male | 27 | 23 | 8 | 4 | 0 | 20 | 10 | 7 | 2 | 2 | 1 | 104 |
No study locations are listed for this record.
Ran from Feb 2013 to primary completion in Nov 2016, 44 months.
Results were first posted in Nov 2017, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir · Ombitasvir/Paritaprevir/Ritonavir · Ribavirin